Zai

Zai Lab Announces Upcoming Presentations in October Investor Conferences

Retrieved on: 
Monday, October 11, 2021
NASDAQ, Health, Zai, Infection, GLOBE, China, SAN, Degenerative disease, Fine chemical

SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in October:

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in October:
    A live webcast of Jefferies China Biotech Virtual Summit will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab Holds Virtual Research and Development Day

Retrieved on: 
Wednesday, September 22, 2021
Tao, Infection, Clinical trial, Business development, CD47, Degenerative disease, International development, Risk, Virtual, Health, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Patient, CDC7, Lung cancer, Coronavirus, Stomach, Growth, Prevalence, SAN, Zai, COVID-19, Drug development, Forward-looking statement, Safety, Gastrointestinal cancer, Investment, Regulatory T cell, GLOBE, Fine chemical, Vaccine, Pharmaceutical industry, Management

SHANGHAI and SAN FRANCISCO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today held a Virtual R&D Day for analysts and investors to provide an in-depth look at its product portfolio and pipeline and its global operations.

Key Points: 
  • At the event, Zai Labs senior leadership provided deep dives into the companys marketed products and clinical candidates, including in-licensed assets to which Zai Lab has Greater China rights and compounds in its internal pipeline to which Zai Lab has global rights.
  • The presentations included discussions of product mechanisms of action, key preclinical and clinical data, differentiating features, and future development plans by both Zai Lab and its partners.
  • He also provided insight into Zai Labs internal research strategy and overviews of the companys internal pipeline products ZL-2309 (CDC7 inhibitor), ZL-1201 (CD47 inhibitor), ZL-2201 (DNA-PK), and ZL-1218 (Treg depleter).
  • Zai Lab has built exciting franchises of product candidates in autoimmune disorders and infectious diseases, with four truly differentiated assets, said Dr. Reinhart.

Zai Lab Announces Upcoming Presentations in September Investor Conferences

Retrieved on: 
Tuesday, August 24, 2021
Infection, GLOBE, Degenerative disease, NASDAQ, Health, Zai, SAN, Fine chemical

SHANGHAI and SAN FRANCISCO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in September:

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in September:
    Live webcasts of the conferences will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Retrieved on: 
Wednesday, August 4, 2021
Video games, Zai, Second Life

We are pleased to be collaborating with Schrdinger, a recognized leader in physics-based computational drug discovery, said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab.

Key Points: 
  • We are pleased to be collaborating with Schrdinger, a recognized leader in physics-based computational drug discovery, said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab.
  • The research program will be conducted jointly by the Schrdinger and Zai Lab scientific teams.
  • The companies will be responsible for their own research program expenses, and under the terms of the collaboration agreement, Zai Lab will make an upfront payment to Schrdinger to help fund Schrdinger's share of research costs.
  • Following the selection of a development candidate, Zai Lab will assume primary responsibility for global development, manufacturing and commercialization.

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Retrieved on: 
Wednesday, August 4, 2021
Oncology, Health, Infectious Diseases, Technology, Software, Pharmaceutical, Biotechnology, Video games, Zai, Second Life, Schrödinger, Zai Lab, SCHRöDINGER, ZAI LAB

We are pleased to be collaborating with Schrdinger, a recognized leader in physics-based computational drug discovery, said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab.

Key Points: 
  • We are pleased to be collaborating with Schrdinger, a recognized leader in physics-based computational drug discovery, said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab.
  • The research program will be conducted jointly by the Schrdinger and Zai Lab scientific teams.
  • The companies will be responsible for their own research program expenses, and under the terms of the collaboration agreement, Zai Lab will make an upfront payment to Schrdinger to help fund Schrdinger's share of research costs.
  • Following the selection of a development candidate, Zai Lab will assume primary responsibility for global development, manufacturing and commercialization.

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Clusters of differentiation, Clinical medicine, Medicine, Immunology, Bispecific monoclonal antibody, CD47, CD3, Zai, Monoclonal antibodies

Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules.

Key Points: 
  • Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules.
  • For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies.
  • We are pleased to expand our strategic collaboration, which leverages both companies unique research capabilities and gives Zai Lab access to MacroGenics proprietary technologies to expand our innovative oncology portfolio on a global basis.
  • If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Labs territories.

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Clusters of differentiation, Clinical medicine, Medicine, Immunology, Bispecific monoclonal antibody, CD47, CD3, Zai, Monoclonal antibodies

Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules.

Key Points: 
  • Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules.
  • For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies.
  • We are pleased to expand our strategic collaboration, which leverages both companies unique research capabilities and gives Zai Lab access to MacroGenics proprietary technologies to expand our innovative oncology portfolio on a global basis.
  • If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Labs territories.

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

Retrieved on: 
Tuesday, June 1, 2021
Health sciences, Health, KRAS, Royalty payment, Zai, Clinical trial

Under the terms of the agreement,Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China.

Key Points: 
  • Under the terms of the agreement,Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China.
  • Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation.
  • Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China.
  • Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib inGreater China.

Zai Lab Announces Upcoming Presentations in June Investor Conferences

Retrieved on: 
Tuesday, May 25, 2021
Financial markets, Hong Kong Exchanges and Clearing, Finance, Zai, Money

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in June:

Key Points: 
  • SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in June:
    Live webcasts of the conferences will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab Announces First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Biology, Programmed cell death, PARP, Cellular processes, Poly (ADP-ribose) polymerase, Adenosine diphosphate ribose, Poly(ADP-ribose) glycohydrolase, Poly(adp-ribose) polymerase family member 14, Polymerase, Zai

b'SHANGHAI and SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results for the first quarter of 2021, along with recent product highlights and corporate updates.\n\xe2\x80\x9cZai Lab continued to execute well in all aspects of the business during the first quarter,\xe2\x80\x9d said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.

Key Points: 
  • b'SHANGHAI and SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results for the first quarter of 2021, along with recent product highlights and corporate updates.\n\xe2\x80\x9cZai Lab continued to execute well in all aspects of the business during the first quarter,\xe2\x80\x9d said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.
  • I believe that the future of Zai Lab has never been brighter.\xe2\x80\x9d\nZEJULA is an oral, once-daily small-molecule poly ADP-ribose polymerase (PARP) 1/2 inhibitor.
  • In addition, in April 2021, Zai Lab announced the closing of a global follow-on offering.
  • These forward-looking statements should not be relied upon as representing Zai Lab\xe2\x80\x99s views as of any date subsequent to the date of this press release.\n'